NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT01194791 2017-04-25
LENDEXAL
PETHEMA Foundation
Phase 2 Completed